Open Access

Advantages of one step nucleic acid amplification (OSNA) whole node assay in sentinel lymph node (SLN) analysis in breast cancer

  • Ana Santaballa1,
  • Helena De La Cueva1Email author,
  • Carmen Salvador1,
  • Ana M García-Martínez2,
  • María J Guarín2,
  • David Lorente1,
  • Laura Palomar1,
  • Ismael Aznar3,
  • Fernando Dobón3 and
  • Pilar Bello4

Received: 24 July 2013

Accepted: 18 September 2013

Published: 17 October 2013



The purpose of this study is to present our first results of sentinel node analysis (SLN) by one step nucleic acid amplification (OSNA) in routine clinical practice in our centre and compare them with the results of classic histopathological analysis in a historical cohort from our same institution.


407 patients (total study population) with early breast cancer and no clinical nodal involvement underwent SLN biopsy in our institution. The SLN was analysed by OSNA in 164 biopsies. OSNA results were compared with the conventional histopathology study of 244 patients who had undergone SLN biopsy previously. The characteristics of the patients in both groups were evaluated and a comparison was made of the rate of metastases detected by both methods and of the surgical procedures needed in each group. We also investigated the state of non-sentinel lymph nodes if micrometastases where found in SLN.


SLN biopsy result was considered as positive in 45 patients (28%) in the OSNA group and in 58 in the historical group (24%). There was no difference in the rate of macrometastases (16,5% for OSNA, 20% for HE) but we found differences in the rate of micrometastases (11% for OSNA and 3,6% for HE p = 0.0007). Axillary lymphadenectomy (ALND) was performed in 43/45 cases in the OSNA group and in 51/58 of the historical group. In all patients diagnosed by OSNA, ALND was performed during the initial surgical procedure. In the historical cohort ALND was performed during the initial surgical procedure in 41 patients and in a second surgical procedure in 10 patients. Patients from both groups with micrometastases in the SLN had no metastases in other nodes when the ALND was performed.


OSNA analysis allows the detection of SLN metastases as precisely as conventional pathology with an increased detection of micrometastases. The OSNA method can reduce the need of a deferred lymphadenectomy.


Sentinel lymph node biopsyBreast cancerMolecular analysisMicrometastases


Selective sentinel node biopsy has replaced axillary lymph node dissection due to its lower morbidity and equivalent prognosis in the long-term (Giuliano et al. 1997; Krag et al. 2010). The presence of nodal metastases is an important prognostic factor and it can help in the asssessment of the need for adjuvant therapy after surgery. The conventional approach in the study for nodal metastases has been staining with haematoxylin-eosin (HE) and immunohistochemistry (IHC). This technique allows analysis during the primary breast tumour surgery, with some sections of the node analysed during the primary procedure, although the remaining sections have to be studied in a deferred manner, which increases the risk of losing valuable information during the surgical procedure.

The one-step acid amplification method (OSNA) detects and quantifies by polymerase chain reaction (PCR) the presence of mRNA of cytokeratin 19 in the whole node (Tsujimoto et al. 2007). It is more time-consuming than the HE study but it can be performed intraoperatively (Osako et al. 2011; Sagara et al. 2011).

The purpose of this study is to present our first results with the OSNA assay performed in a routine clinical setting in 163 patients with invasive and in situ breast cancer, examine their consistency with the classic HE study and evaluate the potential implications for the locorregional treatment of breast cancer patients.

Patients and methods


In the Hospital Universitari i Politècnic La Fe of Valencia 164 consecutive sentinel node biopsy procedures were performed in 163 patients with in situ and early breast cancer between March 2006 and December 2011, studied by OSNA technique. This analysis was performed intraoperatively and if metastases (both micro or macrometastases) were found axillary lymphadenectomy was practiced at the same time. This study has received the approval of the ethical local committee (Comité Ético de Investigación Científica del Hospital La Fe).

For comparison, 244 controls were used as a historical cohort; they were treated between March 2000 and April 2007 in the same hospital, and their sentinel node analysis was performed by the HE and immunohistochemical method.

In both groups, the criteria for sentinel node biopsy were: tumours up to 5 cm in size with no clinical involvement according to physical examination and ultrasound of the axilla. Table 1 shows the patient characteristics. Statistical analysis was performed with SPSS software, using the Chi square statistical test for associations between parameters of interest.
Table 1

Patient characteristics



OSNA cohort (n=164)

Historical cohort (n=244)

Age, median (range)


58 (33–86)

57 (30–93)

Pathologic tumour size, mean (range) mm


16.63 (0–60)

14.16 (0–55)

Tumour histology




Ductal invasive



Lobular invasive



Other subtypes invasive



SBR grade













Oestrogen receptor







Progesterone receptor







HER2 status










Ki 67

≤ 10%



> 10%






Study of SLN by OSNA

After the fatty tissue was removed, the SLN was weighed and whole SLN was processed for the OSNA assay, which is based on the principles of the reverse transcription loop-mediated isothermal amplification method. The SLN was homogenized using LYNORHAG lysis buffer (Sysmex Corp., Hyogo, Japan). CK19 mRNA in each lysate was amplified using a LYNOAMP BC gene amplification reagent (Sysmex Corp.), then a 2-μl sample of each lysate was subjected to an RT-LAMP reaction. The CK19 mRNA copy number was detected by measuring the rise time based on a standard curve using an RD-100i (Sysmex Corp.).

The SLN was assessed as OSNA - when the CK 19 mRNA copy number was fewer than 2.5 × 102 copies μl, OSNA + when it was between 2.5 × 102 and 5.0 × 103 copies μl, and OSNA ++ when it was more than 5.0 × 103 copies μl. The OSNA assay is sometimes inhibited by inhibitory materials resulting in false negative (< 250 copies μl) reactions that may be resolved as positive (≥ 250 copies μl) reactions by simple dilution (1:10). However, the values of these reactions after dilution are less reliable for the quantitative assessment and were evaluated as + inhibition (+I).

Study of sentinel node by IHC

The classical pathological study was based on a first-time intraoperative evaluation. The node was frozen and serial sections of the node, approximately 2 mm each, were performed. Histological staining of each section was done with haematoxylin-eosin. Subsequently, all complete node sections were fixed in paraffin and histological cuts were performed in intervals of 200 microns, which allowed for immunohistochemical staining with cytokeratin AE1-3 and Cam 5.2 and for the detection of isolated tumour cells.

To classify the findings in the lymph node the definition published in the seventh edition of the AJCC was used, which differentiates isolated tumour cells up to 0.2 mm in maximum diameter detected by immunohistochemistry [ITC or pN0 (i +)], tumour cells groups of more than 0.2 mm and up to 2 mm in diameter (micrometastases or pN1mi) and tumour cell groups with more than 2 mm (macrometastases or pN1a).


Analysis of sentinel node

The incidence of lymph node metastases in the OSNA group was 45 (28%): 27 cases of macrometastases (17%) and 18 micrometastases (11%). In the conventional IHC control group any kind of metastases were found in 71 cases (29%): 49 patients showed macrometastases (20%), 9 micrometastases (4%), and 13 presented ITC (5%). Macrometastases rate differences were not statistically significant. Conversely, the difference in proportion of micrometastases is significant, with an increase of detection rate within the OSNA group (11 vs 4%, p = 0.007).

Axillary lymphadenectomy in first vs. second time

Regarding the axillary surgery performed, all 18 OSNA patients who had micrometastases underwent axillary lymphadenectomy in the same surgical procedure, except in the case of a woman operated for bilateral breast cancer in whom there were micrometastases in the sentinel nodes of both sides and only a left axillary dissection was performed. In 26 of the 27 patients with macrometastases, a lymphadenectomy was performed during the initial surgery, while for one patient no further surgery was done.

Of the 49 women with macroscopically involved nodes in the historical cohort 41 underwent ALND at the same time as the SLN procedure while in the remaining 8 the axillary clearance was performed later, as the results were obtained after the operation. Of the 9 patients with micrometastases ALND was performed in a second time in two patients (these were two women whose primary tumour had to be re-excised due to close surgical margins); the other 7 did not undergo any other axillary surgical procedure.

Analysis of non-sentinel lymph nodes in patients with micrometastases in the SLNB

After extending the number of axillary nodes analysed with axillary lymphadenectomy in patients with micrometastases in the SLN biopsy (2/9 patients in the historical cohort and 17/18 OSNA), there were no more affected lymph nodes outside the sentinel lymph node.


The sentinel node study by the OSNA method is being applied in an increasing number of hospitals. Its advantages over the traditional approach with haematoxylin-eosin and immunohistochemistry (HE/IHC) include the decrease in the workload for the pathologist as the process is largely automated and the ability to analyse the full node instead of just some sections while performing surgery of the primary breast tumour.

Different studies have shown that the OSNA assay has a good correlation with the pathological study (Tsujimoto et al. 2007; Sagara et al. 2011; Li et al.; Tamaki et al. 2009), and it also has a higher sensitivity for the detection of micrometastases (Osako et al. 2011).

In our series we have found a similar rate of macrometastases in SLN analysed by OSNA and HE/IHC but with an increased detection of micrometastases with OSNA.

However, this increase in the number of nodes with micrometastases provides information that is difficult to apply in the clinical setting, as its prognostic value has not been fully clarified. One of the most relevant studies to address this issue is the prospective NSABP B-32 trial, which was designed to evaluate the outcome of SLN biopsy alone compared to axillary dissection, in which 5,611 patients with SLN biopsy were randomized to undergo or not to undergo axillary clearance (Krag et al. 2007). Subsequently, an analysis was published of patients with occult nodal metastases reviewing almost 4000 ganglion blocks (Weaver et al. 2011). At five years, the presence of occult metastases was associated with a lower overall survival, progression free survival and distant metastases free interval compared to node-negative patients. Although this increased risk in the three parameters was statistically significant, the magnitude of the difference in the 5-year Kaplan-Meier estimates of overall survival was only 1.2 percentage points and the authors concluded that this difference might be of little clinical relevance.

The finding of micrometastases in the sentinel node can have an impact on clinical management. In our series all patients with micrometastases in the OSNA group underwent axillary clearance. One of the reasons why it was done was the study of a possible involvement of other lymph nodes, which is estimated to occur in approximately 10-15% of cases of SLN biopsy micrometastases in classical histological studies (Solá et al. 2013; Galimberti et al. 2013; Cserni et al. 2004; Houvenaeghel et al. 2009). In this sense, we cannot draw conclusions from our data since the rate of micrometastases in the HE/IHC group was very low and barely any lymphadenectomies were performed. Published data about the OSNA technique also indicate that the PCR load of cytokeratin 19 correlates with the finding of non-sentinel node metastases (Osako et al. 2011), although in our sample none of 17 patients undergoing lymphadenectomy due to micrometastasis in OSNA had involvement in the other nodes.

Despite the possible presence of other affected lymph nodes there are trials showing that lymphadenectomy can be omitted in patients with micrometastases in the SLN biopsy since their presence does not increase the rate of axillary recurrence (Solá et al. 2013; Galimberti et al. 2013; Guenther et al. 2003; Gant et al. 2003; Langer et al. 2005). Recently, two randomised trials that explore this issue had been published, a Spanish study (Solá et al. 2013) and the IBCSG 23–01 trial (Galimberti et al. 2013). With a recruitment lower than expected, 247 and 932 patients respectively with micrometastases in SLN biopsy were randomly assigned to axillary dissection or no axillary dissection. No differences in terms of disease-free survival after a follow-up of five years were seen.

Probably the long-term monitoring of patients in which micrometastases are detected by OSNA will provide new data in this sense, as it is a method that is more reproducible and allows a more complete analysis of the node than the histopathological analysis (Osako et al. 2011; Tamaki et al. 2009).

Currently in our centre micrometastases in SLN biopsy are not considered an indication for axillary clearance, given the growing literature that supports this decision and the recommendations in this sense of the 2011 St Gallen Consensus Conference (Goldhirsch et al. 2011). We maintain the indication in case of macrometastases although in the future this might be avoided in cases of macrometastases in only one or two sentinel nodes in certain patient, based on the findings of the ACOSOG Z0011 study (Giuliano et al. 2011).

In any case, the full analysis of lymph nodes by OSNA allows us to perform lymphadenectomy in the same surgical procedure in all cases, something not always possible in patients studied by IHC in which the full results can be obtained later. The performance of a single procedure can provide important advantages for the patient, such as avoiding a second operation and a possible delay in the start of adjuvant therapy, as well as lower cost for the institution (Guillen-Paredes et al. 2011).


The sentinel node analysis by OSNA enables reliable results within minutes, allowing axillary lymphadenectomy practice in the same surgery when indicated, i.e. in case of SLN biopsy macrometastases.

The increase in diagnoses of patients with micrometastatic involvement by OSNA should be studied in terms of its prognostic and therapeutic implications.



We would like to thank Dr Roberto Díaz Beveridge for his help with the translation of the manuscript.

Authors’ Affiliations

Medical Oncology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
Anatomic Pathology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
Surgery Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
Nuclear Medicine Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain


  1. Cserni G, Gregori D, Merletti F, et al.: Non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer: metaanalysis of 25 studies. Br JSurg 2004, 91: 1245e52.View ArticleGoogle Scholar
  2. Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al.: Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol 2013, 14(4):297-305. 10.1016/S1470-2045(13)70035-4View ArticleGoogle Scholar
  3. Gant JS, Grant MD, Knox SM, et al.: Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann SurgOncol 2003, 10: 126-130.Google Scholar
  4. Giuliano AE, Jones RC, Brennan M, Statman R: Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997, 15: 2345-2350.Google Scholar
  5. Giuliano AE, Hunt K, Ballman KV, et al.: Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis. JAMA 2011, 305(6):569-575. 10.1001/jama.2011.90View ArticleGoogle Scholar
  6. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ: and the Panel members. Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011, 22: 1736-1747. 10.1093/annonc/mdr304View ArticleGoogle Scholar
  7. Guenther JM, Hansen NM, Di Fronzo LA, et al.: Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg 2003, 138: 52-56. 10.1001/archsurg.138.1.52View ArticleGoogle Scholar
  8. Guillen-Paredes MP, Carrasco-Gonzalez L, Chaves-Benito A, et al.: [One-step nucleic acid amplification (OSNA) assay for sentinel lymph node metastases as an alternative to conventional postoperative histology in breast cancer: A cost-benefit analysis.]. Cir Esp 2011, 89(7):456e62.View ArticleGoogle Scholar
  9. Houvenaeghel G, Nos C, Giard S, et al.: A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J SurgOncol 2009, 35: 690e5.Google Scholar
  10. Krag DN, Anderson SJ, Julian TB, et al.: Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007, 8: 881-888. 10.1016/S1470-2045(07)70278-4View ArticleGoogle Scholar
  11. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al.: Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010, 11(10):927-933. 10.1016/S1470-2045(10)70207-2View ArticleGoogle Scholar
  12. Langer I, Marti WR, Guller U, et al.: Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases. Ann Surg 2005, 241: 152-158.Google Scholar
  13. Li D, Xu X, Chen J, Chen J, Yang B, Yang W, et al.: Utility of one-step nucleic acid amplification (OSNA) assay in detecting breast cancer metastases of sentinel lymph nodes in a Chinese population. Breast Cancer Mar 21. [Epub ahead of print]Google Scholar
  14. Osako T, Iwase T, Kimura K, Yamashita K, Horii R, Yanagisawa A, et al.: Intraoperative molecular assay for sentinel lymph node metastases in early stage breast cancer: a comparative analysis between one-step nucleic acid amplification whole node assay and routine frozen section histology. Cancer 2011, 117: 4365-4374. 10.1002/cncr.26060View ArticleGoogle Scholar
  15. Sagara Y, Ohi Y, Matsukata A, Yotsumoto D, Baba S, Tamada S, et al.: Clinical application of the one-step acid amplification method to detect sentinel node metastases in breast cancer. Breast Cancer 2011. doi:10.1007/s12282-011-0324-zGoogle Scholar
  16. Solá M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R, et al.: Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol 2013, 20(1):120-127. 10.1245/s10434-012-2569-yView ArticleGoogle Scholar
  17. Tamaki Y, Akiyama F, Iwase T, Kaneko T, Tsuda H, Sato K, et al.: Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay. Clin Cancer Res 2009, 15(8):2879-2884. 10.1158/1078-0432.CCR-08-1881View ArticleGoogle Scholar
  18. Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F, et al.: One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res 2007, 13(16):4807-4816. 10.1158/1078-0432.CCR-06-2512View ArticleGoogle Scholar
  19. Weaver DL, Takamaru A, Krag DN, et al.: Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 2011, 364: 412-421. 10.1056/NEJMoa1008108View ArticleGoogle Scholar


© Santaballa et al.; licensee Springer. 2013

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.